{"success":true,"data":{"pressRelease":{"id":"44290","rtpr_id":"nGNXVKMSB","ticker":"IMMP","exchange":"NASDAQ","all_tickers":["IMMP","IMM"],"title":"Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm","author":"Globe Newswire","published_at":"2026-05-25T16:00:00.325Z","article_body":"NEW YORK, May 25, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC,\na nationally recognized investor-rights law firm, announces that a class\naction lawsuit has been filed against Immutep Limited (NASDAQ: IMMP) and\ncertain of its officers.\n\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired Immutep securities between March\n24, 2025 and March 12, 2026, both dates inclusive (the “Class Period”).\nSuch investors are encouraged to join this case by visiting the firm’s site:\nbgandg.com/IMMP.\n(https://www.globenewswire.com/Tracker?data=I_Sbuzl6jNXshZOlHhR-v7E4FbFkEdNq-v6R1Wxpy44qWz89UWeQQzoo5QcQY4g1I4yj4ByQYB8F8Pi0SbD3yAMmSeAOd2Cjx1nw82IFg7m3qclusGyp8ub3BJKmrV3nCU9U2daS8CHx38GIyw0yfwgTyQZHnwUMziQIA30YCzg=)\n\nImmutep Case Details\n\nThe Complaint alleges that, throughout the Class Period, Defendants made\nmaterially false and misleading statements and/or failed to disclose that:\n\n(1) Defendants concealed and misrepresented the status and prospects of the\nCompany’s TACTI-004 trial by relying on prior positive efficacy and safety\nreadouts of efti in other studies, including TACTI-002 and INSIGHT-003, to\nsuggest continued success; \n(2) Defendants’ statements regarding the TACTI-004 trial’s “strong\noperational progress” and the anticipated timing of its interim futility\nanalysis lacked a reasonable basis given then-existing clinical data; \n(3) based on their access to internal clinical data, analyses, and reports,\nDefendants knew or recklessly disregarded that the risk of the TACTI-004 trial\nfailing to meet its primary efficacy and/or safety endpoints had materially\nincreased; and \n(4) as a result, Defendants’ statements about the Company’s business,\noperations, and prospects were materially false and misleading at all relevant\ntimes.\n\nWhat's Next for Immutep Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm’s site: bgandg.com/IMMP.\n(https://www.globenewswire.com/Tracker?data=I_Sbuzl6jNXshZOlHhR-v1D1N_-1qOsWERAlo0Bwn_dnbeT62NlhUghAkCpCpQ96gUDl2boeJ-suC-8XWbXHMO7Qk_NsmjvkCVzlpSu-T8SI8kBEUR6RL-KezpQUlN1uD2QIUiMTtKf-KmNnRetUAOFdz72Lj2xwIocUGf8D-B8=)\nor you may contact Peretz Bronstein, Esq. or his Client Relations Manager,\nNathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you\nsuffered a loss in Immutep you have until July 6, 2026, to request that the\nCourt appoint you as lead plaintiff. Your ability to share in any recovery\ndoesn't require that you serve as lead plaintiff.\n\nNo Cost to Immutep Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on\na contingency fee basis. That means we will ask the court to reimburse us for\nout-of-pocket expenses and attorneys’ fees, usually a percentage of the\ntotal recovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Immutep Securities Class Action?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.globenewswire.com/Tracker?data=5mB8ZWdilA-2OSsQcUJd9hjQskByJpXJ4GWZ2TdSmNxJ6fInV5vsyGjHY4sADFDwqh5TUBtsJamVh1DJRg_u2QYo7aBn7xWVhtps_yc50pVE5Jwobbl0zQ41bjJQJ-ERg49a8tAyfsYcTRrGhGR-Nw==),\nFounding Partner of Bronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.globenewswire.com/Tracker?data=6bGwII68FSv5oXxizCj8iirTZxxFa4_5IK4YAUXjVRY2YRddBb0SQ5FEnQX1eLePllgFoOrGE9-AGMCY3XK3YudOs1hdieGBzvOOlQGjcP5jRHveB7ajFOPXvCFN8ZHNV0pMLsG-_QutrUV96-4Ofg==),\nX\n(https://www.globenewswire.com/Tracker?data=4LUCz2Dh5zqtEYcxw1Fi-ZtvUAFAbRCBzx-IEDJYlIrK2_b0uRM6YKlQoAkcFiBrG8LcXc9keohXuxnkMRjliA==),\nFacebook\n(https://www.globenewswire.com/Tracker?data=SMWGnlOd1tCt4KjJCXytLykrXexRZzeuEq_RgGs5cF_NLw-GvUp7qqhg7gjF4noJy2s2EjBRlo5ba7TL0PK3tiUggvL8h3GgRUTu8dmZZd0=),\nor Instagram\n(https://www.globenewswire.com/Tracker?data=FJpMH8rjow6STasgwHhL_tlj20RWQyOm2S_WBdXT3LH2HzHd_2NewpCH-iSLF6gUBs6ubW84we-AHYTIBdo-bbXTofOZBaE5K5_n4xnEHpc=).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 | info@bgandg.com\n\nAttorney advertising.\nPrior results do not guarantee similar outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1a031130-a9cc-48ff-b281-d1e47c9a91a5)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXVKMSB","title":"Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm","author":"Globe Newswire","ticker":"IMMP","created":"2026-05-25T16:00:00.325Z","tickers":["IMMP","IMM"],"exchange":"NASDAQ","article_body":"NEW YORK, May 25, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC,\na nationally recognized investor-rights law firm, announces that a class\naction lawsuit has been filed against Immutep Limited (NASDAQ: IMMP) and\ncertain of its officers.\n\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired Immutep securities between March\n24, 2025 and March 12, 2026, both dates inclusive (the “Class Period”).\nSuch investors are encouraged to join this case by visiting the firm’s site:\nbgandg.com/IMMP.\n(https://www.globenewswire.com/Tracker?data=I_Sbuzl6jNXshZOlHhR-v7E4FbFkEdNq-v6R1Wxpy44qWz89UWeQQzoo5QcQY4g1I4yj4ByQYB8F8Pi0SbD3yAMmSeAOd2Cjx1nw82IFg7m3qclusGyp8ub3BJKmrV3nCU9U2daS8CHx38GIyw0yfwgTyQZHnwUMziQIA30YCzg=)\n\nImmutep Case Details\n\nThe Complaint alleges that, throughout the Class Period, Defendants made\nmaterially false and misleading statements and/or failed to disclose that:\n\n(1) Defendants concealed and misrepresented the status and prospects of the\nCompany’s TACTI-004 trial by relying on prior positive efficacy and safety\nreadouts of efti in other studies, including TACTI-002 and INSIGHT-003, to\nsuggest continued success; \n(2) Defendants’ statements regarding the TACTI-004 trial’s “strong\noperational progress” and the anticipated timing of its interim futility\nanalysis lacked a reasonable basis given then-existing clinical data; \n(3) based on their access to internal clinical data, analyses, and reports,\nDefendants knew or recklessly disregarded that the risk of the TACTI-004 trial\nfailing to meet its primary efficacy and/or safety endpoints had materially\nincreased; and \n(4) as a result, Defendants’ statements about the Company’s business,\noperations, and prospects were materially false and misleading at all relevant\ntimes.\n\nWhat's Next for Immutep Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm’s site: bgandg.com/IMMP.\n(https://www.globenewswire.com/Tracker?data=I_Sbuzl6jNXshZOlHhR-v1D1N_-1qOsWERAlo0Bwn_dnbeT62NlhUghAkCpCpQ96gUDl2boeJ-suC-8XWbXHMO7Qk_NsmjvkCVzlpSu-T8SI8kBEUR6RL-KezpQUlN1uD2QIUiMTtKf-KmNnRetUAOFdz72Lj2xwIocUGf8D-B8=)\nor you may contact Peretz Bronstein, Esq. or his Client Relations Manager,\nNathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you\nsuffered a loss in Immutep you have until July 6, 2026, to request that the\nCourt appoint you as lead plaintiff. Your ability to share in any recovery\ndoesn't require that you serve as lead plaintiff.\n\nNo Cost to Immutep Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on\na contingency fee basis. That means we will ask the court to reimburse us for\nout-of-pocket expenses and attorneys’ fees, usually a percentage of the\ntotal recovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Immutep Securities Class Action?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.globenewswire.com/Tracker?data=5mB8ZWdilA-2OSsQcUJd9hjQskByJpXJ4GWZ2TdSmNxJ6fInV5vsyGjHY4sADFDwqh5TUBtsJamVh1DJRg_u2QYo7aBn7xWVhtps_yc50pVE5Jwobbl0zQ41bjJQJ-ERg49a8tAyfsYcTRrGhGR-Nw==),\nFounding Partner of Bronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.globenewswire.com/Tracker?data=6bGwII68FSv5oXxizCj8iirTZxxFa4_5IK4YAUXjVRY2YRddBb0SQ5FEnQX1eLePllgFoOrGE9-AGMCY3XK3YudOs1hdieGBzvOOlQGjcP5jRHveB7ajFOPXvCFN8ZHNV0pMLsG-_QutrUV96-4Ofg==),\nX\n(https://www.globenewswire.com/Tracker?data=4LUCz2Dh5zqtEYcxw1Fi-ZtvUAFAbRCBzx-IEDJYlIrK2_b0uRM6YKlQoAkcFiBrG8LcXc9keohXuxnkMRjliA==),\nFacebook\n(https://www.globenewswire.com/Tracker?data=SMWGnlOd1tCt4KjJCXytLykrXexRZzeuEq_RgGs5cF_NLw-GvUp7qqhg7gjF4noJy2s2EjBRlo5ba7TL0PK3tiUggvL8h3GgRUTu8dmZZd0=),\nor Instagram\n(https://www.globenewswire.com/Tracker?data=FJpMH8rjow6STasgwHhL_tlj20RWQyOm2S_WBdXT3LH2HzHd_2NewpCH-iSLF6gUBs6ubW84we-AHYTIBdo-bbXTofOZBaE5K5_n4xnEHpc=).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 | info@bgandg.com\n\nAttorney advertising.\nPrior results do not guarantee similar outcomes.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/1a031130-a9cc-48ff-b281-d1e47c9a91a5)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-25T16:00:00.368287955Z","server_sent_at_ms":1779724800368},"received_at":"2026-05-25T16:00:00.612Z","source_url":null},"analysis":{"id":"33725","press_release_id":"44290","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Bronstein, Gewirtz & Grossman LLC announced that a class action lawsuit has been filed against Immutep Limited and certain officers.\n\nThe complaint alleges materially false and misleading statements regarding the status and prospects of the TACTI-004 clinical trial for efti.\n\nThe law firm is soliciting investors who purchased securities between March 24, 2025, and March 12, 2026, to join the case or seek lead plaintiff status by July 6, 2026.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace","namedEntities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner, Bronstein, Gewirtz & Grossman, LLC"},{"name":"Nathan Miller","role":"Client Relations Manager, Bronstein, Gewirtz & Grossman, LLC"}],"products":["TACTI-004","efti","TACTI-002","INSIGHT-003"],"companies":[{"name":"Bronstein, Gewirtz & Grossman, LLC","relationship":"plaintiff law firm"},{"name":"Immutep Limited","ticker":"IMMP","relationship":"defendant"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a plaintiff law-firm solicitation issued by Bronstein, Gewirtz & Grossman LLC. It is a routine marketing release urging investors to join a class action, not an issuer disclosure or a court ruling. Per guardrails, these are scored as low-impact noise."},"tickerRelevance":{"others":[],"primary":"IMMP"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bronstein, Gewirtz & Grossman LLC announced that a class action lawsuit has been filed against Immutep Limited and certain officers.\n\nThe complaint alleges materially false and misleading statements regarding the status and prospects of the TACTI-004 clinical trial for efti.\n\nThe law firm is soliciting investors who purchased securities between March 24, 2025, and March 12, 2026, to join the case or seek lead plaintiff status by July 6, 2026.","key_figures":{},"named_entities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner, Bronstein, Gewirtz & Grossman, LLC"},{"name":"Nathan Miller","role":"Client Relations Manager, Bronstein, Gewirtz & Grossman, LLC"}],"products":["TACTI-004","efti","TACTI-002","INSIGHT-003"],"companies":[{"name":"Bronstein, Gewirtz & Grossman, LLC","relationship":"plaintiff law firm"},{"name":"Immutep Limited","ticker":"IMMP","relationship":"defendant"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-25T16:01:22.136Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":24986,"modelName":"george-droid-qwen-72b"}}